Intellia Announces Proposed Public Offering of Common Stock
Rhea-AI Summary
Intellia (Nasdaq: NTLA) announced an underwritten public offering of $150 million of common stock, with a 30-day underwriter option to purchase up to an additional 15% of the shares. All offered shares are to be sold by Intellia.
The offering is being led by Jefferies, Goldman Sachs and Citigroup, is subject to market and other conditions, and will be made under an automatic shelf registration on Form S-3ASR (File No. 333-275740). A preliminary prospectus supplement will be filed with the SEC.
Positive
- Proceeds of $150 million to fund operations and programs
- Underwritten offering provides execution certainty if completed
- Shelf registration (Form S-3ASR) enables capital flexibility
Negative
- Share issuance may cause dilution for existing shareholders
- Offering completion is uncertain and subject to market conditions
News Market Reaction – NTLA
In the Apr 28 session, NTLA gained 1.23%, reflecting a mild positive market reaction. Argus tracked a peak move of +7.0% during that session. Argus tracked a trough of -30.2% from its starting point during tracking. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility. Trading volume was elevated at 2.3x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 03 | Inducement grants | Neutral | +1.3% | Announcement of 67,150 RSUs to 13 new employees under inducement plan. |
| Mar 06 | Inducement grants | Neutral | +3.4% | Grant of 16,500 RSU shares to six new employees per Nasdaq Rule 5635(c)(4). |
| Mar 03 | Clinical data update | Positive | -11.9% | Longer-term HAE data for lonvo-z showing durable attack reduction in Phase 1/2. |
| Mar 02 | Regulatory update | Positive | +12.1% | FDA lifted clinical hold on MAGNITUDE Phase 3 ATTR-CM trial, enrollment to resume. |
| Feb 26 | Earnings & pipeline | Positive | +6.4% | Q4/FY25 results with HAELO Phase 3 timing and cash of $605.1M funding into H2 2027. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often saw price gains on regulatory and earnings updates, but one major positive clinical data event led to a double‑digit decline, indicating occasional negative reactions even to favorable developments.
Over the last six months, Intellia’s key disclosures ranged from equity inducement grants to pivotal clinical and financial updates. Positive regulatory progress, such as the FDA lifting the MAGNITUDE Phase 3 clinical hold on Mar 2, 2026, and the Q4 2025 earnings update with $605.1M in cash and runway into H2 2027, both coincided with gains. However, strong HAE clinical data on Mar 3, 2026 matched with a steep selloff, showing that good news has not always translated into positive price moves.
Key Terms
underwritten public offering financial
prospectus supplement regulatory
prospectus regulatory
securities and exchange commission regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it has commenced an underwritten public offering of
Jefferies, Goldman Sachs & Co. LLC and Citigroup are acting as joint book-running managers for the proposed offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The shares of common stock are being offered by Intellia pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-275740) that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 24, 2023 and automatically became effective upon filing. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and may be obtained, when available, from: Jefferies LLC, by mail at Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@jefferies.com; Goldman Sachs & Co. LLC, by mail at Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Tel: 800-831-9146).
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease.
Forward-Looking Statements
This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations regarding the proposed public offering; uncertainties related to market conditions and statements regarding the timing, size and expected proceeds of the proposed public offering; the safety, tolerability, efficacy, advancement and success of Intellia’s clinical programs; and Intellia’s ability to successfully execute its business and strategic plans, including the advancement, development and commercialization of its product candidates.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia’s relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies’ evaluation of regulatory filings and other information related to our product candidates, including nex-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials; the risk that any one or more of Intellia’s product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia’s other product candidates; and risks related to Intellia’s reliance on collaborations, including that its collaboration with Regeneron Pharmaceuticals, Inc. will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission, including its quarterly reports on Form 10-Q. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.
Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com
Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicommunications.com
